Assessing Smooth Pursuit Eye Movements Using Eye-Tracking Technology in Patients with Schizophrenia Under Treatment: A Pilot Study.

Schizophrenia is a complex disorder that affects mental organization and cognitive functions, including concentration and memory. One notable manifestation of cognitive changes in schizophrenia is a diminished ability to scan and perform tasks related to visual inspection. From the three evaluable aspects of the ocular movements (saccadic, smooth pursuit, and fixation) in particular, smooth pursuit eye movement (SPEM) involves the tracking of slow moving objects and is closely related to attention, visual memory, and processing speed. However, evaluating smooth pursuit in clinical settings is challenging due to the technical complexities of detecting these movements, resulting in limited research and clinical application. This pilot study investigates whether the quantitative metrics derived from eye-tracking data can distinguish between patients with schizophrenia under treatment and healthy controls. The study included nine healthy participants and nine individuals receiving treatment for schizophrenia. Gaze trajectories were recorded using an eye tracker during a controlled visual tracking task performed during a clinical visit. Spatiotemporal analysis of gaze trajectories was performed by evaluating three different features: polygonal area, colocalities, and direction difference. Subsequently, a support vector machine (SVM) was used to assess the separability between healthy individuals and those with schizophrenia based on the identified gaze trajectory features. The results show statistically significant differences between the control and subjects with schizophrenia for all the computed indexes ( < 0.05) and a high separability achieving around 90% of accuracy, sensitivity, and specificity. The results suggest the potential development of a valuable clinical tool for the evaluation of SPEM, offering utility in clinics to assess the efficacy of therapeutic interventions in individuals with schizophrenia.